ArticleInternational journal of molecular sciences2023
Co-Delivery of Ylang Ylang Oil of
Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 31 citations in OpenAlex.
- Ylang Ylang Essential Oil in Malignant and Non-Malignant Cells: Comparative Mitophagy-Related Transcriptional Responses.Pharmaceuticals (Basel, Switzerland) · 2026Article
- The role of circulating MiR-34a-5p and MiR-let7a-5p as a diagnostic tumor markers in breast cancer a cross-sectional analysis.Molecular biology reports · 2026Article
- Advanced nanoplatforms for oxaliplatin-based breast cancer therapy: targeted delivery, stimuli-responsive design, and translational challenges.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Dual-Function Lipid-Based Nanovector Strategy for Glioblastoma Immunotherapy: STING Activation and M1 Microglia Polarization.Drug development research · 2026Review
- Purine Scaffold in Agents for Cancer Treatment.ACS omega · 2025Review
- Biologically Active Compounds of Malaysian Medicinal and Aromatic Plants.Progress in the chemistry of organic natural products · 2025Review
- Metal-based molecules in the treatment of cancer: From bench to bedside.Oncology research · 2025Review
- Sustainable Nanomedicine: Enhancement of Asplatin's Cytotoxicity In Vitro and In Vivo Using Green-Synthesized Zinc Oxide Nanoparticles Formed via Microwave-Assisted and Gambogic Acid-Mediated Processes.Molecules (Basel, Switzerland) · 2024Article
- Synergistic Enhancement of Carboplatin Efficacy through pH-Sensitive Nanoparticles Formulated Using Naturally DerivedPharmaceutics · 2024Article
- Liposomal Formulations of Metallodrugs for Cancer Therapy.International journal of molecular sciences · 2024Review
- Article
- Hijacking 5-Fluorouracil Chemoresistance in Triple Negative Breast Cancer via microRNAs-Loaded Chitosan Nanoparticles.International journal of molecular sciences · 2024Article
- Emerging tendencies for the nano-delivery of gambogic acid: a promising approach in oncotherapy.RSC advances · 2024Review
- Article
- Recent Innovations of Mesoporous Silica Nanoparticles Combined with Photodynamic Therapy for Improving Cancer Treatment.Pharmaceutics · 2023Review
- PEGylated Chitosan Nanoparticles Loaded with Betaine and Nedaplatin Hamper Breast Cancer: In Vitro and In Vivo Studies.ACS omega · 2023Article
- Newly Synthesized Anticancer Purine Derivatives InhibitingACS omega · 2023Article
- Box-Behnken design of thermo-responsive nano-liposomes loaded with a platinum(iv) anticancer complex: evaluation of cytotoxicity and apoptotic pathways in triple negative breast cancer cells.Nanoscale advances · 2023Article
- Nedaplatin/Pharmaceutics · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 2 countries.
Funding
Abstract
Smart pH-responsive niosomes loaded with either Oxaliplatin (Ox), Ylang ylang essential oil (Y-oil), or co-loaded with both compounds (Ox-Y) (Ox@NSs, Y@NSs, and Ox-Y@NSs, respectively) were formulated utilizing the thin film method. The developed nanocontainers had a spherical morphology with mean particle sizes lower than 170 nm and showed negative surface charges, high entrapment efficiencies, and a pH-dependent release over 24 h. The prepared pH-responsive niosomes' cytotoxicity was tested against the invasive triple-negative breast cancer (MDA-MB-231) cells, compared to free OX and Y-oil. All niosomal formulations loaded with Ox and/or Y-oil significantly improved cytotoxic activity relative to their free counterparts. The Ox-Y@NSs demonstrated the lowest IC50 (0.0002 µg/mL) when compared to Ox@NSs (0.006 µg/mL) and Y@NSs (18.39 µg/mL) or unloaded Ox (0.05 µg/mL) and Y-oil (29.01 µg/mL)
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.